Oncopeptides
Oncopeptides AB is a privately held clinical stage company developing melflufen, a peptidase potentiated therapy for multiple myeloma.
Business Model:
Revenue: $0
Employees: 201-500
Rankings
Industries / Tags:
Detailed Oncopeptides Information
Geographic Data
Address:
City: Stockholm
State: Stockholms Lan
Zip:
Country: Sweden
Financial Info
Stage:
post ipo debt
Raised Last:
$31M
Raised Total:$240M
Social
Metrics
327,061Website Global Rank
127,124Website Monthly Traffic
Twitter Followers
Description
Oncopeptides is a clinical stage company backed by HealthCap and Industrifonden that has raised approximately 16.5 MEUR in Early Stage and Series A financing to 2015. Oncopeptides lead compound, named melflufen, is a peptidase potentiated therapy within oncology. Melflufen is a very potent anti-angiogenetic compound, triggers rapid, robust, and irreversible DNA damage and exerts it cytotoxicity through alkylation of DNA. Melflufen is currently undergoing Phase 2 efficacy studies in patients with relapsed and relapsed-refractory multiple myeloma. The peptidase targeting causes melflufen and its metabolites to accumulate in the diseased cells. This results in targeted delivery of the active moieties to the cancer cells, and thereby better treatment of the disease.
Contact Phone:
Contact Email:
Oncopeptides went public on 3/2/2017 on the STO
Listed Exchange:
STO
IPO Date:
3/2/2017
IPO Valuation:
$209M
Ticker Symbol:
ONCO
IPO Price:
$5.063736480511604/share
Amount Raised:
$71M
Live
Opened: -/share
| EBITDA | - |
| Total Cash | - |
| Total Debt | - |
| Total Revenue | - |
| Total Profit (Gross) | - |
| PE Ratio | - |
| Announced Date | Company | Transaction | Money Raised |
|---|
| Announced Date | Transaction | Number of Investors | Money Raised | Lead Investors | 9/2022 | Grant | $0 |
Vinnova Vinnova Vinnova Vinnova |
3/2021 | Post-IPO Equity | 2 | $130.4M |
Artisan Partners Bain Capital Artisan Partners Bain Capital |
6/2019 | Post-IPO Equity | $78.3M | 5/2013 | Series A | 1 | - |
Industrifonden Industrifonden |
11/2022 | Post-IPO Debt | 1 | $31.2M |
European Investment Bank European Investment Bank |
9/2022 | Grant | 1 | $467.1k |
Vinnova Vinnova Vinnova Vinnova |
5/2013 | Series A | 1 | - |
Industrifonden Industrifonden |
|---|
| Announced Date | Name | Price |
|---|
Employee Departments
Employee States
|
|
Revenue: 0 - 100000 Employees: Industry: Software |
Details
|
|
|
Revenue: 0 - 100000 Employees: 51 - 500 Industry: Education |
Details
|
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Blockchain |
Details
|
|
|
Revenue: 0 - 100000 Employees: 11 - 50 Industry: Industrial |
Details
|
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Advertising |
Details
|
